Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a prospective, randomised and controlled pilot study

ISRCTN ISRCTN92101486
DOI https://doi.org/10.1186/ISRCTN92101486
Secondary identifying numbers N/A
Submission date
16/11/2006
Registration date
13/12/2006
Last edited
24/09/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Stephan C Bischoff
Scientific

University of Hohenheim
Department of Nutritional Medicine
Fruwirthstrasse 12
Stuttgart
70599
Germany

Study information

Study designProspective, randomised and controlled pilot study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymLactulose
Study objectivesInflammatory bowel diseases (IBD), commonly referred to as Crohn’s Disease (CD) and Ulcerative Colitis (UC) are recurrent aggressive inflammatory conditions of multifactorial etiology, which to date are not well understood. Interactions of genetic background, disturbance of the mucosal barrier, dysregulation of intestinal immune responses as well as bacterial and other environmental factors were found to play a role in the development of IBD.

Aims of trial:
Positive clinical and histological efficacy of lactulose in patients with IBD.
Ethics approval(s)The study was approved by the Ethical Committee of the Hannover Medical School, dated 7th February 2000 (ref: No 2229). All procedures were in accordance with the Declaration of Helsinki.
Health condition(s) or problem(s) studiedInflammatory Bowel Disease (IBD), Crohn’s Disease (CD), Ulcerative Colitis (UC)
InterventionThe aim of the present study was to investigate clinical effects of the prebiotic "lactulose" in IBD patients.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Oral lactulose
Primary outcome measureImprovement of clinical activity
Secondary outcome measures1. Quality of life
2. Medication
3. Endoscopic score
4. Laboratory parameters:
a. Haemoglobin (Hb) values
b. Haematocrit values
c. Orsomucoid (Ors)
d. Albumin (Alb)
e. Immunoglobulins G, A and M (IgG, IgA and IgM respectively)
f. Alpha-1-antitrypsin
g. pH in faeces
Overall study start date01/08/2000
Completion date01/07/2003

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexBoth
Target number of participants70
Key inclusion criteriaTo be included in the trial, patients had to present IBD. The majority of patients enrolled in this study were hospitalised because of symptoms of active disease and in most of them the clinical activity was confirmed by elevated Clinical Activity Index (CAI) scores in UC or elevated Crohn’s Disease Activity Index (CDAI) scores. The diagnosis of IBD was confirmed by classical clinical and endoscopic means according to the German and Austrian guidelines for UC and CD.
Key exclusion criteria1. Surgery during study period
2. Other diseases than IBD
Date of first enrolment01/08/2000
Date of final enrolment01/07/2003

Locations

Countries of recruitment

  • Germany

Study participating centre

University of Hohenheim
Stuttgart
70599
Germany

Sponsor information

Solvay Pharmaceuticals GmbH (Germany)
Industry

Hans-Böckler-Allee 20
Hannover
30173
Germany

Website http://www.solvay.de/
ROR logo "ROR" https://ror.org/01xscrc43

Funders

Funder type

Industry

Funding was supplied by Solvay Pharmaceuticals GmbH, which covered expenses for drugs and equipment (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 04/09/2007 Yes No